Literature DB >> 6744269

Enhancement of the sensitivity of human colon cancer cells to growth inhibition by acivicin achieved through inhibition of nucleic acid precursor salvage by dipyridamole.

P H Fischer, R Pamukcu, G Bittner, J K Willson.   

Abstract

This study was undertaken to determine if salvage of nucleic acid precursors might constitute a mechanism of resistance to acivicin in human colon cancer cells and, if so, to establish whether dipyridamole, an inhibitor of nucleoside and nucleobase transport, can block the salvage process and restore sensitivity to acivicin. Acivicin inhibited the replication of human colon cancer cells (VACO 5) in vitro in a dose- and time-dependent fashion. In addition, marked cell lysis was evident after a 24-hr exposure to acivicin at concentrations greater than 1 microgram/ml. The primary metabolic effect of acivicin was depletion of the cytidine triphosphate and guanosine triphosphate pools. Adenosine triphosphate levels were also reduced, but apparently as a consequence of the guanosine triphosphate depletion. VACO 5 cells exposed to acivicin (3 micrograms/ml) efficiently salvaged low levels (1 micron) of cytidine, guanosine, and guanine and could, therefore, restore the depleted nucleotide pools. The combination of cytidine and guanosine, but not either nucleoside alone, provided significant protection against the growth-inhibitory properties of acivicin. Dipyridamole, at a noncytotoxic concentration (5 microM), blocked repletion of the cytidine triphosphate and guanosine triphosphate pools in cells exposed to acivicin and the nucleic acid precursors. As a result, the growth-inhibitory effects of acivicin were maintained. The salvage of cytidine was particularly sensitive to inhibition by dipyridamole, and no restoration of cytidine triphosphate pools was evident. The cellular uptake of a variety of nucleic acid precursors was differentially sensitive to inhibition by dipyridamole. The 50% inhibitory dose values ranged from 0.01 to 2.5 microM for cytidine and uridine, respectively. The results of this study indicate that, although the replication of VACO 5 cells was inhibited by acivicin, low levels of nucleosides and nucleobases can circumvent the cytotoxicity. Dipyridamole effectively blocked the salvage pathways and restored the sensitivity of the cancer cells to the antiproliferative actions of acivicin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744269

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness.

Authors:  A Hofer; D Steverding; A Chabes; R Brun; L Thelander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Relevance of glutamine metabolism to tumor cell growth.

Authors:  M A Medina; F Sánchez-Jiménez; J Márquez; A Rodríguez Quesada; I Núñez de Castro
Journal:  Mol Cell Biochem       Date:  1992-07-06       Impact factor: 3.396

3.  A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Authors:  H Bailey; G Wilding; K D Tutsch; R Z Arzoomanian; D Alberti; M B Tombes; J L Grem; D R Spriggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

5.  Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and Tretinoin.

Authors:  G K Górski; L E McMorrow; M H Donaldson
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

6.  Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.

Authors:  S S Cao; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 7.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.

Authors:  H N Jayaram; K Murayama; K Pillwein; W Zhen; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.